Oesophageal Cancer Trial, Recruiting (NCT05775939)

Oesophageal Cancer Trial, Recruiting NCT05775939 Sponsor: Thomas Jefferson University Condition: Oesophageal Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05775939 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Oesophageal Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are willing and able to sign and date a consent form agreeing to take part
You are willing to follow all study requirements and are available for the full length of the study
You are male or female, aged 18 or older
Your doctor expects you to live for at least 3 months
Your radiation oncologist estimates that your heart will receive a certain minimum level of radiation dose (at least 5 Gy) during your treatment (confirm with trial site)
You have been diagnosed with lung cancer or esophageal cancer, confirmed through a tissue or cell sample test
You are scheduled to receive a course of radiation treatment for lung or esophageal cancer, whether on a standard schedule or a shorter, higher-dose schedule

Who may not be able to join:

You are unable to have a type of scan called an FDG PET-CT scan for medical reasons, as determined by your doctor
Your radiation treatment is planned as a short palliative course of 20 Gy given in 5 sessions (a lower-dose treatment aimed at relieving symptoms rather than treating the cancer directly)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yevgeniy Vinogradskiy, Thomas Jefferson University

Phone: 215-955-3605

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05775939

Sponsor: Thomas Jefferson University

Phase: Not Applicable

Status: Recruiting

Condition: Oesophageal Cancer

Trial contact: 215-955-3605

More information: https://clinicaltrials.gov/study/NCT05775939

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are willing and able to sign and date a consent form agreeing to take part
You are willing to follow all study requirements and are available for the full length of the study
You are male or female, aged 18 or older
Your doctor expects you to live for at least 3 months
Your radiation oncologist estimates that your heart will receive a certain minimum level of radiation dose (at least 5 Gy) during your treatment (confirm with trial site)
You have been diagnosed with lung cancer or esophageal cancer, confirmed through a tissue or cell sample test
You are scheduled to receive a course of radiation treatment for lung or esophageal cancer, whether on a standard schedule or a shorter, higher-dose schedule

Who may not be able to join:

You are unable to have a type of scan called an FDG PET-CT scan for medical reasons, as determined by your doctor
Your radiation treatment is planned as a short palliative course of 20 Gy given in 5 sessions (a lower-dose treatment aimed at relieving symptoms rather than treating the cancer directly)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Thomas Jefferson University

Registry

ClinicalTrials.gov

Start date

20 January 2023

Est. completion

1 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in mean standardized uptake value (SUV) changes in the heart

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov